- Home
- GGZ vs FATE Comparison
GGZ vs FATE Comparison
Compare GGZ & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGZ | FATE |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | 181 |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 115.1M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | GGZ | FATE |
|---|---|---|
| Price | $15.04 | $0.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.92 |
| AVG Volume (30 Days) | 12.8K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 5.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | N/A | ★ $7,137,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.79 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.43 | $0.66 |
| 52 Week High | $12.50 | $1.99 |
Technical Indicators
Market Signals| Indicator | GGZ | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 69.03 | 37.81 |
| Support Level | $14.75 | $0.98 |
| Resistance Level | $14.95 | $1.12 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 72.44 | 8.33 |
Price Performance
Historical ComparisonAbout GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.